153 related articles for article (PubMed ID: 35836303)
21. Long leukocyte telomere length in prostate cancer patients at diagnosis is associated with poor metastasis-free and cancer-specific survival.
Svenson U; Roos G; Wikström P
Tumour Biol; 2017 Feb; 39(2):1010428317692236. PubMed ID: 28222672
[TBL] [Abstract][Full Text] [Related]
22. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
23. Radical prostatectomy versus watchful waiting in early prostate cancer.
Bill-Axelson A; Holmberg L; Ruutu M; Garmo H; Stark JR; Busch C; Nordling S; Häggman M; Andersson SO; Bratell S; Spångberg A; Palmgren J; Steineck G; Adami HO; Johansson JE;
N Engl J Med; 2011 May; 364(18):1708-17. PubMed ID: 21542742
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.
Zhang M; Guan J; Huo YL; Song YS; Chen LZ
Asian J Androl; 2019; 21(4):387-392. PubMed ID: 30860083
[TBL] [Abstract][Full Text] [Related]
25. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Yousefi K; Davicioni E; Ghadessi M; Johnson MH; Sundi D; Tosoian JJ; Han M; Humphreys EB; Partin AW; Walsh PC; Trock BJ; Schaeffer EM
Eur Urol; 2016 Mar; 69(3):496-504. PubMed ID: 25922274
[TBL] [Abstract][Full Text] [Related]
26. Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
Rosenberg JE; Jung JH; Edgerton Z; Lee H; Lee S; Bakker CJ; Dahm P
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013641. PubMed ID: 32813279
[TBL] [Abstract][Full Text] [Related]
27. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.
Hegde JV; Chen MH; Mulkern RV; Fennessy FM; D'Amico AV; Tempany CM
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):e101-7. PubMed ID: 23040223
[TBL] [Abstract][Full Text] [Related]
28.
Haney NM; Faisal FA; Lu J; Guedes LB; Reuter VE; Scher HI; Eastham JA; Marchionni L; Joshu C; Gopalan A; Lotan TL
J Urol; 2020 Feb; 203(2):344-350. PubMed ID: 31502941
[TBL] [Abstract][Full Text] [Related]
29. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
[TBL] [Abstract][Full Text] [Related]
30. Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer.
Lee MC; Erickson TR; Stock S; Howard LE; De Hoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Klaassen Z; Freedland SJ; Wallis CJD
J Urol; 2022 Mar; 207(3):592-600. PubMed ID: 34694910
[TBL] [Abstract][Full Text] [Related]
31. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.
Zhang AY; Chiam K; Haupt Y; Fox S; Birch S; Tilley W; Butler LM; Knudsen K; Comstock C; Rasiah K; Grogan J; Mahon KL; Bianco-Miotto T; Ricciardelli C; Böhm M; Henshall S; Delprado W; Stricker P; Horvath LG; Kench JG
Int J Cancer; 2019 Mar; 144(5):1151-1159. PubMed ID: 30288742
[TBL] [Abstract][Full Text] [Related]
32. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
33. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort.
Johnson MH; Ross AE; Alshalalfa M; Erho N; Yousefi K; Glavaris S; Fedor H; Han M; Faraj SF; Bezerra SM; Netto G; Partin AW; Trock BJ; Davicioni E; Schaeffer EM
J Urol; 2016 Nov; 196(5):1436-1444. PubMed ID: 27238617
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of neutrophil-to-lymphocyte ratio as a prognostic indicator in a Singapore cohort of patients with clinically localized prostate cancer treated with prostatectomy.
Lu Y; Huang HH; Lau WKO
World J Urol; 2020 Jan; 38(1):103-109. PubMed ID: 30953141
[TBL] [Abstract][Full Text] [Related]
35. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
36. Are short telomeres predictive of advanced cancer?
Shay JW
Cancer Discov; 2013 Oct; 3(10):1096-8. PubMed ID: 24124228
[TBL] [Abstract][Full Text] [Related]
37. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
38. Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer.
Rybicki BA; Sadasivan SM; Chen Y; Loveless I; Gupta NS; Chitale DA; Williamson SR; Rundle AG; Tang DL
Cancer Epidemiol Biomarkers Prev; 2022 May; 31(5):991-998. PubMed ID: 35247880
[TBL] [Abstract][Full Text] [Related]
39. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.
Bill-Axelson A; Holmberg L; Filén F; Ruutu M; Garmo H; Busch C; Nordling S; Häggman M; Andersson SO; Bratell S; Spångberg A; Palmgren J; Adami HO; Johansson JE;
J Natl Cancer Inst; 2008 Aug; 100(16):1144-54. PubMed ID: 18695132
[TBL] [Abstract][Full Text] [Related]
40. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
